ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ZNTL
YARW (26) WHWK (24) UPB (29) TRDA (16) ⌘ Pro Terminal →

Zentalis Pharmaceuticals Inc. (ZNTL) — RQD Stock Rating Cockpit

$1.85 -5.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.83

Zentalis Pharmaceuticals Inc. (ZNTL) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $185.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZNTL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZNTL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.85 (-5.61% 1D, market cap $185.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ZNTL ranks #629 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZNTL compare to YARW and WHWK in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZNTL carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, YARW (Yarrow Bioscience Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $185.2M) and WHWK (Whitehawk Therapeutics Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $184.7M). Among the 5-stock peer group, ZNTL leads on earnings multiple (N/A) while ZNTL leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZNTL?
▼

Per ZNTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001725160), Zentalis Pharmaceuticals Inc. generated $427.9M in revenue (+534.6% YoY), -$137.1M in net income, and -$125.2M in free cash flow against $289.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.83 (-1.20%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$7 Bull$2 Base$1 Bear
📬 FREE ZNTL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZNTL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY ZNTL SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$2.52-8.7% Next Q
Q2 (-2Q)
39
Grade E$2.30-10% Next Q
Q3 (-1Q)
37
Grade E$2.07-10.6% Next Q
Current
34
Grade E$1.85-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZNTL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZNTL currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.91) and Max Pain ($1.94) forces dealer call-delta covering toward $7.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZNTL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZNTL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
31.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE11% OF RANGE
L: $1$1.85H: $7
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ZNTL

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (27)

8/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like ZNTL
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZNTL)

  • ✓Walkthrough of ZNTL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ZNTL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.75%▼ SUPPORT BREAKDOWN
2026-11-03O $1.99H $1.99L $1.85C $1.85VOL 1.33M
RES: $5.24SUP: $2.55SMA50: $2.91SMA200: $3.45
$5.84$4.76$3.68$2.60$1.51RES $5.24SUP $2.55$1.852026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZNTL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZNTL Butterfly Map → + Track ZNTL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +534.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ZNTL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZNTL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZNTL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZNTL)

Health Care Rank #629 of 1015 ⚔️ YARW vs ZNTL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZNTL vs. YARW, WHWK, UPB, TRDA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Zentalis Pharmaceuticals Inc. (ZNTL) ranks #629 by composite RQD confidence (34/100, grade E) and #583 by equity capitalization ($185.6M). Within this direct 5-issuer industry benchmark cohort, ZNTL leads on earnings valuation at N/A trailing P/E, while ZNTL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ZNTL currently leads its immediate peer cohort in composite quantitative strength at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ZNTL ACTIVE
Zentalis Pharmaceuticals Inc.
E 34/100 — — -35.0% -5.61% $185.6M Benchmark Subject
YARW
Yarrow Bioscience Inc.
E 26/100 — — -35.0% -9.90% $185.2M /yarw-vs-zntl →
WHWK
Whitehawk Therapeutics Inc.
E 24/100 — 89.4% -35.0% -3.70% $184.7M /whwk-vs-zntl →
UPB
Upstream Bio Inc.
E 29/100 — — -35.0% -1.76% $186.8M /upb-vs-zntl →
TRDA
Entrada Therapeutics Inc.
E 16/100 — — -35.0% +12.68% $176.6M /trda-vs-zntl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001725160 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zentalis Pharmaceuticals Inc. (ZNTL) reported GAAP revenue of $427.9M (+534.6% vs. FY2024 revenue of $67.4M , and -49.0% cumulative change since FY2023) , GAAP net income of -$137.1M, operating cash flow of -$125.2M, and free cash flow of -$125.2M (+26.8% YoY). On the balance sheet, ZNTL closed FY2025 with $289.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $427.9M -$137.1M -$125.2M -$125.2M $289.0M —
FY2024 (FY) 2024-12-31 $67.4M -$165.9M -$170.9M -$171.1M $430.3M —
FY2023 (FY) 2023-12-31 $838.6M -$292.3M -$207.8M -$207.8M — —

3. ZNTL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZNTL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.85 (-5.61% 1D, market cap $185.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ZNTL ranks #629 in composite RQD confidence.

How does ZNTL compare to YARW and WHWK in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZNTL carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, YARW (Yarrow Bioscience Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $185.2M) and WHWK (Whitehawk Therapeutics Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $184.7M). Among the 5-stock peer group, ZNTL leads on earnings multiple (N/A) while ZNTL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ZNTL?

Per ZNTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001725160), Zentalis Pharmaceuticals Inc. generated $427.9M in revenue (+534.6% YoY), -$137.1M in net income, and -$125.2M in free cash flow against $289.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ZNTL trading relative to its 50-day, 200-day, and 52-week technical levels?

ZNTL last traded at $1.85 (-5.61% on volume of 1,074,052 shares), positioning the stock -36.43% below its 50-day simple moving average ($2.91) and -46.38% below its 200-day simple moving average ($3.45). Across its 52-week range of $1.21 to $6.95, ZNTL sits at the 11.1% percentile with a 14-day RSI of 31.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.62 to $2.08).

Direct Sub-Reports: ZNTL RQD Cockpit ZNTL 12M Forecast ZNTL Earnings & Move ZNTL Dividends & DRIP ZNTL Insiders & 13F ZNTL Whale Options ZNTL Profit Sankey ZNTL News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

ZNTL — Zentalis Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Zentalis Pharmaceuticals Inc. (ZNTL) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.85 (-5.61% 1D, market capitalization $185.6M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Zentalis Pharmaceuticals Inc. (ZNTL) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..2B. FY 2024 revenue was $67.4M, while FY 2025 and FY 2023 revenue were —. — for detailed product descriptions, customer segments, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Zentalis Pharmaceuticals Inc. (ZNTL) reported $427.9M in annual revenue (up from $67.4M in FY2024, +534.6% YoY) and -$137.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($838.6M revenue, -$292.3M net income) through FY2025, ZNTL scaled operating cash flow to -$125.2M and free cash flow to -$125.2M, backed by $289.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.21 – $6.95 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph lists no upstream or downstream dependencies and no sector correlation links, so second-order ripples cannot be mapped from the source data. A prospective investor should watch whether trial data and analyst coverage changes move the stock independently of the cash burn shown in the SEC financials.

  • Key Question #1: Can ZNTL sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $427.9M and free cash flow of -$125.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ZNTL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ZNTL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Zentalis Pharmaceuticals Inc. (ZNTL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZNTL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZNTL Bull vs. Bear Conversation Board — What's Your Call at $1.85?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZNTL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ZNTL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $2.41 (+23.0%)
📌 Pinned Debate

Leerink assumed coverage with an Outperform rating and shares rose on cancer trial data, indicating near-term catalyst momentum.

The street is overcomplicating Zentalis Pharmaceuticals Inc. (ZNTL). Leerink assumed coverage with an Outperform rating and shares rose on cancer trial data, indicating near-term catalyst momentum.. With an RQD score of 34/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $2.12.

RetailWhale_TX 🐂 BULL

@ShortSeller_Dan Shorting a 3/20 institutional whale-flow stock at $1.96 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $1.65 (-15.8%)
Spot @ $1.96

ROIC of -35% and operating losses in every reported period indicate ongoing cash burn that the balance sheet must fund.

Careful chasing ZNTL at $1.96. ROIC of -35% and operating losses in every reported period indicate ongoing cash burn that the balance sheet must fund.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.65 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%